je.st
news
Tag: 17th
Northwest District | 7-20-17 | 2030 NW 17th Ave | Design Review - NOTICE | LU 17-197039 DZ
2017-07-20 23:22:42| PortlandOnline
PDF Document, 3,891kbCategory: Neighbors West/Northwest
Tags: design
review
notice
district
Finalists revealed in the 17th annual BIFM Awards
2017-07-20 13:18:00| BIFM News
Tags: annual
awards
revealed
17th
Irvington | 6-30-17 | 3015 NE 17th Ave | Historic Resource Review - NOTICE | LU 17-180969 HR
2017-06-30 23:36:27| PortlandOnline
PDF Document, 2,690kbCategory: Northeast Coalition of Neighbors
Tags: review
notice
resource
ave
Goose Hollow | 6-16-17 | 817 SW 17th Ave | Parking Review - HEARINGS OFFICER DECISION | LU 16-273139 PR
2017-06-21 18:09:35| PortlandOnline
PDF Document, 19,940kbCategory: Neighbors West/Northwest Decisions
Tags: review
decision
pr
officer
Updated KEYTRUDA (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
2016-12-06 14:20:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. Language: English Contact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »